A painless microneedle array patch for glucose-responsive smart insulin delivery, enhancing health and qualify of life of people with diabetes. This is the first prototype for the closed-loop transdermal drug delivery. (PNAS, 2015; Nature Biomedical Engineering, 2020)
In situ formed sprayable/ injectable bioresponsive gels with immunotherapeutics, e.g., immune checkpoint inhibitor for local delivery, associated with primary tumor and post-surgical treatment. (Science Translational Medicine, 2018; Nature Nanotechnology, 2019)
Construction of synthetic artificial beta cells (AβCs) with a 'vesicles-in-vesicle' superstructure equipped with a membrane-fusion machinery for glucose-responsive insulin delivery. (Nature Chemical Biology, 2017)
Platelets loaded with immune checkpoint antibodies for surgical site targeting and in situ activation for inhibiting tumor recurrence and metastasis. This strategy can also be used for inhibiting recurrence of leukemia. (Nature Biomedical Engineering, 2017; Nature Biomedical Engineering, 2018)
Our iMedication Lab is interested in integrating biomaterials design, biomacromolecular engineering, and micro/nano-fabrication towards new drug delivery strategies, which apply stimuli-responsive systems for delivering and/or releasing therapeutics in dose-, spatial- and temporal-controlled manners. Our current focus is to leverage physiology for bioresponsive drug delivery through cellular carriers or biomimetic synthetic vehicles.